Today, the CFO and VP, Corp. Development of Vericel Corp (NASDAQ: VCEL), Gerard Michel, bought shares of VCEL for $400K.
Following Gerard Michel’s last VCEL Buy transaction on September 17, 2014, the stock climbed by 7.4%.
See today’s analyst top recommended stocks >>
Based on Vericel Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $18.03 million and GAAP net loss of $7.66 million. In comparison, last year the company earned revenue of $16.95 million and had a GAAP net loss of $2.39 million. Currently, Vericel Corp has an average volume of 634K. The Company has a Price to Book ratio of 17.6974.
Starting in March 2016, VCEL received 27 Buy ratings in a row. Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $15.00, reflecting a -31.7% downside. Nine different firms, including BTIG and Chardan Capital, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel.
